[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBEiMKc-cJ5eR4Ec43eBiYuNWYwo53hKP9ERyQ8mhD0I":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"University of Nottingham",[4],449,false,70,12,1051897,3,389,[14,17,20,22,25,27,29,32],{"name":15,"count":16},"Healthy",16,{"name":18,"count":19},"Obesity",14,{"name":21,"count":9},"Stroke",{"name":23,"count":24},"Irritable Bowel Syndrome",11,{"name":26,"count":24},"Multiple Sclerosis",{"name":28,"count":24},"Asthma",{"name":30,"count":31},"Sarcopenia",10,{"name":33,"count":34},"Insulin Resistance",9,[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07569419","Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis","2026-08","Linaclotide 290 micrograms",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05414292","Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)","2027-05-01","Rapamune (sirolimus) 1Mg",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,80,98,119,168,206,237,262,290,308,332,350,372,397,423,447,473,491,509,527,553,571,599,617,642,666,690,714,740,758,783,808,826,853,878,913,937,961,979,1006,1024,1049,1072,1096,1121,1147,1165,1191,1209,1234,1258,1284,1302,1320,1338,1363,1381,1407,1425,1443,1461,1479,1503,1529,1553,1571,1597,1623,1647,1670,1694,1721,1739,1761,1787,1810,1828,1853,1871,1893,1917],{"intervention":40,"totalTrials":55,"cells":56},1,{"EARLY_PHASE1":57,"PHASE1":69,"PHASE2":72,"PHASE3":74,"PHASE4":76,"NA":78},{"trials":58,"activeCount":55,"soonestReadout":39},[59],{"nctId":37,"briefTitle":38,"status":60,"phases":61,"primaryCompletion":39,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":67},"RECRUITING",[47],"2026-10","2026-03-09",26,[66],"Cystic Fibrosis (CF)",[40,68],"Lactose placebo pill",{"trials":70,"activeCount":71},[],0,{"trials":73,"activeCount":71},[],{"trials":75,"activeCount":71},[],{"trials":77,"activeCount":71},[],{"trials":79,"activeCount":71},[],{"intervention":68,"totalTrials":55,"cells":81},{"EARLY_PHASE1":82,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":94,"NA":96},{"trials":83,"activeCount":55,"soonestReadout":39},[84],{"nctId":37,"briefTitle":38,"status":60,"phases":85,"primaryCompletion":39,"completion":62,"start":63,"enrollment":64,"conditions":86,"interventions":87},[47],[66],[40,68],{"trials":89,"activeCount":71},[],{"trials":91,"activeCount":71},[],{"trials":93,"activeCount":71},[],{"trials":95,"activeCount":71},[],{"trials":97,"activeCount":71},[],{"intervention":45,"totalTrials":55,"cells":99},{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":110},{"trials":101,"activeCount":71},[],{"trials":103,"activeCount":71},[],{"trials":105,"activeCount":71},[],{"trials":107,"activeCount":71},[],{"trials":109,"activeCount":71},[],{"trials":111,"activeCount":55,"soonestReadout":44},[112],{"nctId":42,"briefTitle":43,"status":60,"phases":113,"primaryCompletion":44,"completion":44,"start":114,"enrollment":16,"conditions":115,"interventions":118},[52],"2021-08-06",[116,117],"Muscle Atrophy","Age-Related Sarcopenia",[45],{"intervention":120,"totalTrials":11,"cells":121},"Secretin",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":137,"PHASE3":150,"PHASE4":152,"NA":166},{"trials":123,"activeCount":71},[],{"trials":125,"activeCount":71},[126],{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":131,"completion":132,"start":133,"enrollment":9,"conditions":134,"interventions":136},"NCT01452217","Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers","COMPLETED",[48],"2011-09","2011-10","2010-09",[135],"Chronic Pancreatitis",[120],{"trials":138,"activeCount":71},[139],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"NCT02458118","Pancreatic Perfusion Using Secretin and MRI","UNKNOWN",[48,49],"2016-04","2016-06","2012-06",15,[135],[120],{"trials":151,"activeCount":71},[],{"trials":153,"activeCount":71},[154],{"nctId":155,"briefTitle":156,"status":129,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":31,"conditions":160,"interventions":162},"NCT01134848","A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers",[51],"2010-02","2009-01",[161],"Sphincter of Oddi Dysfunction",[163,164,165,120,165],"Morphine","Neostigmine","0.9% saline",{"trials":167,"activeCount":71},[],{"intervention":169,"totalTrials":170,"cells":171},"Bevacizumab",2,{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":204},{"trials":173,"activeCount":71},[],{"trials":175,"activeCount":71},[],{"trials":177,"activeCount":71},[],{"trials":179,"activeCount":71},[],{"trials":181,"activeCount":71},[182,193],{"nctId":183,"briefTitle":184,"status":142,"phases":185,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":192},"NCT02594423","Strategies for Management of Corneal Neovascularisation",[51],"2017-08","2018-08","2015-12",40,[191],"Corneal Neovascularisation",[169],{"nctId":194,"briefTitle":195,"status":142,"phases":196,"primaryCompletion":197,"completion":187,"start":198,"enrollment":199,"conditions":200,"interventions":202},"NCT02530801","Strategies for Management of Recurrent Pterygium",[51],"2018-04","2017-01",25,[201],"Recurrent Pterygium",[169,203],"5 fluorouracil",{"trials":205,"activeCount":71},[],{"intervention":207,"totalTrials":170,"cells":208},"Bisacodyl 5 milligram",{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":217,"NA":235},{"trials":210,"activeCount":71},[],{"trials":212,"activeCount":71},[],{"trials":214,"activeCount":71},[],{"trials":216,"activeCount":71},[],{"trials":218,"activeCount":71},[219,228],{"nctId":220,"briefTitle":221,"status":129,"phases":222,"primaryCompletion":223,"completion":223,"start":224,"enrollment":9,"conditions":225,"interventions":227},"NCT04132661","MRI Assessment of Mode of Action of Bisacodyl, Single Dose",[51],"2022-11-01","2020-09-25",[226],"Constipation",[207],{"nctId":229,"briefTitle":230,"status":129,"phases":231,"primaryCompletion":223,"completion":223,"start":232,"enrollment":9,"conditions":233,"interventions":234},"NCT04129788","MRI Assessment of Mode of Action of Bisacodyl, Multiple Doses",[51],"2020-10-04",[226],[207],{"trials":236,"activeCount":71},[],{"intervention":238,"totalTrials":55,"cells":239},"Semaglutide Pen Injector [Ozempic]",{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":248,"NA":260},{"trials":241,"activeCount":71},[],{"trials":243,"activeCount":71},[],{"trials":245,"activeCount":71},[],{"trials":247,"activeCount":71},[],{"trials":249,"activeCount":71},[250],{"nctId":251,"briefTitle":252,"status":142,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":259},"NCT05606471","Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets",[51],"2023-07-28","2021-09-15",45,[258],"Type 2 Diabetes Mellitus in Obese",[238],{"trials":261,"activeCount":71},[],{"intervention":263,"totalTrials":55,"cells":264},"Intravenous paracetamol",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":288},{"trials":266,"activeCount":71},[],{"trials":268,"activeCount":71},[],{"trials":270,"activeCount":71},[],{"trials":272,"activeCount":71},[],{"trials":274,"activeCount":71},[275],{"nctId":276,"briefTitle":277,"status":142,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":286},"NCT02425254","Preemptive Paracetamol for Postoperative Pain",[51],"2017-06","2018-07","2016-01",50,[284,285],"Pain","Surgical Wound",[263,287],"Intravenous saline 0.9%",{"trials":289,"activeCount":71},[],{"intervention":287,"totalTrials":55,"cells":291},{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":300,"NA":306},{"trials":293,"activeCount":71},[],{"trials":295,"activeCount":71},[],{"trials":297,"activeCount":71},[],{"trials":299,"activeCount":71},[],{"trials":301,"activeCount":71},[302],{"nctId":276,"briefTitle":277,"status":142,"phases":303,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":304,"interventions":305},[51],[284,285],[263,287],{"trials":307,"activeCount":71},[],{"intervention":309,"totalTrials":55,"cells":310},"Ondansetron",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":330},{"trials":312,"activeCount":71},[],{"trials":314,"activeCount":71},[],{"trials":316,"activeCount":71},[],{"trials":318,"activeCount":71},[],{"trials":320,"activeCount":71},[321],{"nctId":322,"briefTitle":323,"status":129,"phases":324,"primaryCompletion":325,"completion":325,"start":159,"enrollment":326,"conditions":327,"interventions":329},"NCT00745004","Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D)",[51],"2011-07",150,[328],"Irritable Bowel Syndrome With Diarrhoea",[309],{"trials":331,"activeCount":71},[],{"intervention":203,"totalTrials":55,"cells":333},{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":340,"PHASE4":342,"NA":348},{"trials":335,"activeCount":71},[],{"trials":337,"activeCount":71},[],{"trials":339,"activeCount":71},[],{"trials":341,"activeCount":71},[],{"trials":343,"activeCount":71},[344],{"nctId":194,"briefTitle":195,"status":142,"phases":345,"primaryCompletion":197,"completion":187,"start":198,"enrollment":199,"conditions":346,"interventions":347},[51],[201],[169,203],{"trials":349,"activeCount":71},[],{"intervention":351,"totalTrials":55,"cells":352},"Dichloroacetate",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":370},{"trials":354,"activeCount":71},[],{"trials":356,"activeCount":71},[],{"trials":358,"activeCount":71},[],{"trials":360,"activeCount":71},[],{"trials":362,"activeCount":71},[363],{"nctId":364,"briefTitle":365,"status":142,"phases":366,"primaryCompletion":279,"completion":279,"start":367,"enrollment":189,"conditions":368,"interventions":369},"NCT02469337","Role of Preoperative Carbohydrates Drinks, Dichloroacetate and Exercise on Postoperative Muscle Insulin Resistance",[51],"2012-05",[33],[351],{"trials":371,"activeCount":71},[],{"intervention":373,"totalTrials":55,"cells":374},"Penicillin VK",{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":381,"PHASE4":383,"NA":395},{"trials":376,"activeCount":71},[],{"trials":378,"activeCount":71},[],{"trials":380,"activeCount":71},[],{"trials":382,"activeCount":71},[],{"trials":384,"activeCount":71},[385],{"nctId":386,"briefTitle":387,"status":129,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":394},"NCT00552799","RCT to Investigate if Prophylactic Antibiotics Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg",[51],"2011-11","2006-07",274,[393],"Cellulitis\u002FErysipelas of the Leg",[373],{"trials":396,"activeCount":71},[],{"intervention":398,"totalTrials":55,"cells":399},"IMP Pioglitozone",{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":406,"PHASE4":408,"NA":421},{"trials":401,"activeCount":71},[],{"trials":403,"activeCount":71},[],{"trials":405,"activeCount":71},[],{"trials":407,"activeCount":71},[],{"trials":409,"activeCount":71},[410],{"nctId":411,"briefTitle":412,"status":413,"phases":414,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":420},"NCT01134835","PPAR-gamma: a Novel Therapeutic Target for Asthma?","TERMINATED",[51],"2012-02","2012-07","2010-06",68,[28],[398],{"trials":422,"activeCount":71},[],{"intervention":424,"totalTrials":55,"cells":425},"Offer of voucher for cost-free Nicotine Replacement Therapy",{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":445},{"trials":427,"activeCount":71},[],{"trials":429,"activeCount":71},[],{"trials":431,"activeCount":71},[],{"trials":433,"activeCount":71},[],{"trials":435,"activeCount":71},[436],{"nctId":437,"briefTitle":438,"status":129,"phases":439,"primaryCompletion":158,"completion":133,"start":440,"enrollment":441,"conditions":442,"interventions":444},"NCT00775944","Trial Comparing Different Methods of Support With Stopping Smoking (PORTSSS\u002FStop Together Trial)",[51],"2009-02",2591,[443],"Tobacco Smoking",[424],{"trials":446,"activeCount":71},[],{"intervention":448,"totalTrials":55,"cells":449},"Doxycycline",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":471},{"trials":451,"activeCount":71},[],{"trials":453,"activeCount":71},[],{"trials":455,"activeCount":71},[],{"trials":457,"activeCount":71},[],{"trials":459,"activeCount":71},[460],{"nctId":461,"briefTitle":462,"status":129,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":470},"NCT00989742","Doxycycline In Lymphangioleiomyomatosis (LAM)",[51],"2013-01","2009-07",24,[468,469],"Lymphangioleiomyomatosis","Tuberous Sclerosis",[448],{"trials":472,"activeCount":71},[],{"intervention":163,"totalTrials":55,"cells":474},{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":489},{"trials":476,"activeCount":71},[],{"trials":478,"activeCount":71},[],{"trials":480,"activeCount":71},[],{"trials":482,"activeCount":71},[],{"trials":484,"activeCount":71},[485],{"nctId":155,"briefTitle":156,"status":129,"phases":486,"primaryCompletion":158,"completion":158,"start":159,"enrollment":31,"conditions":487,"interventions":488},[51],[161],[163,164,165,120,165],{"trials":490,"activeCount":71},[],{"intervention":164,"totalTrials":55,"cells":492},{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":507},{"trials":494,"activeCount":71},[],{"trials":496,"activeCount":71},[],{"trials":498,"activeCount":71},[],{"trials":500,"activeCount":71},[],{"trials":502,"activeCount":71},[503],{"nctId":155,"briefTitle":156,"status":129,"phases":504,"primaryCompletion":158,"completion":158,"start":159,"enrollment":31,"conditions":505,"interventions":506},[51],[161],[163,164,165,120,165],{"trials":508,"activeCount":71},[],{"intervention":165,"totalTrials":55,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":525},{"trials":512,"activeCount":71},[],{"trials":514,"activeCount":71},[],{"trials":516,"activeCount":71},[],{"trials":518,"activeCount":71},[],{"trials":520,"activeCount":71},[521],{"nctId":155,"briefTitle":156,"status":129,"phases":522,"primaryCompletion":158,"completion":158,"start":159,"enrollment":31,"conditions":523,"interventions":524},[51],[161],[163,164,165,120,165],{"trials":526,"activeCount":71},[],{"intervention":528,"totalTrials":55,"cells":529},"Ondansetron 8mg",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":551},{"trials":531,"activeCount":71},[],{"trials":533,"activeCount":71},[],{"trials":535,"activeCount":71},[],{"trials":537,"activeCount":71},[],{"trials":539,"activeCount":71},[540],{"nctId":541,"briefTitle":542,"status":129,"phases":543,"primaryCompletion":544,"completion":544,"start":545,"enrollment":16,"conditions":546,"interventions":549},"NCT03833999","Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea",[51],"2019-06-27","2018-10-16",[547,309,548],"Motility Disorder of Intestine","Small Bowel Water",[528,550],"Lactulose",{"trials":552,"activeCount":71},[],{"intervention":550,"totalTrials":55,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":569},{"trials":556,"activeCount":71},[],{"trials":558,"activeCount":71},[],{"trials":560,"activeCount":71},[],{"trials":562,"activeCount":71},[],{"trials":564,"activeCount":71},[565],{"nctId":541,"briefTitle":542,"status":129,"phases":566,"primaryCompletion":544,"completion":544,"start":545,"enrollment":16,"conditions":567,"interventions":568},[51],[547,309,548],[528,550],{"trials":570,"activeCount":71},[],{"intervention":572,"totalTrials":55,"cells":573},"Letrozole",{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":582,"NA":597},{"trials":575,"activeCount":71},[],{"trials":577,"activeCount":71},[],{"trials":579,"activeCount":71},[],{"trials":581,"activeCount":71},[],{"trials":583,"activeCount":71},[584],{"nctId":585,"briefTitle":586,"status":129,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":595},"NCT00478504","Letrozole Versus Clomifene Citrate for Ovulation Induction",[51],"2014-06","2014-09","2007-05",159,[593,594],"Infertility","Polycystic Ovarian Syndrome",[572,596],"Clomifene citrate",{"trials":598,"activeCount":71},[],{"intervention":596,"totalTrials":55,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":615},{"trials":602,"activeCount":71},[],{"trials":604,"activeCount":71},[],{"trials":606,"activeCount":71},[],{"trials":608,"activeCount":71},[],{"trials":610,"activeCount":71},[611],{"nctId":585,"briefTitle":586,"status":129,"phases":612,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":613,"interventions":614},[51],[593,594],[572,596],{"trials":616,"activeCount":71},[],{"intervention":618,"totalTrials":55,"cells":619},"Ciclesonide",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":628,"NA":640},{"trials":621,"activeCount":71},[],{"trials":623,"activeCount":71},[],{"trials":625,"activeCount":71},[],{"trials":627,"activeCount":71},[],{"trials":629,"activeCount":71},[630],{"nctId":631,"briefTitle":632,"status":129,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":639},"NCT01171365","Small Particle Steroids in Refractory Asthma",[51],"2013-10","2013-12","2010-01",30,[28],[618],{"trials":641,"activeCount":71},[],{"intervention":643,"totalTrials":55,"cells":644},"CRH",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":664},{"trials":646,"activeCount":71},[],{"trials":648,"activeCount":71},[],{"trials":650,"activeCount":71},[],{"trials":652,"activeCount":71},[],{"trials":654,"activeCount":71},[655],{"nctId":656,"briefTitle":657,"status":129,"phases":658,"primaryCompletion":464,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":663},"NCT01763281","Imaging the Effect of Experimental Stress on Small and Large Bowel Water During Fructose Absorption",[51],"2013-02","2012-10",20,[15],[643],{"trials":665,"activeCount":71},[],{"intervention":667,"totalTrials":55,"cells":668},"Mesalazine",{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":677,"NA":688},{"trials":670,"activeCount":71},[],{"trials":672,"activeCount":71},[],{"trials":674,"activeCount":71},[],{"trials":676,"activeCount":71},[],{"trials":678,"activeCount":71},[679],{"nctId":680,"briefTitle":681,"status":129,"phases":682,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":687},"NCT01316718","Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)",[51],"2013-09","2011-03",108,[328],[667],{"trials":689,"activeCount":71},[],{"intervention":691,"totalTrials":55,"cells":692},"Budesonide",{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":712},{"trials":694,"activeCount":71},[],{"trials":696,"activeCount":71},[],{"trials":698,"activeCount":71},[],{"trials":700,"activeCount":71},[],{"trials":702,"activeCount":71},[703],{"nctId":704,"briefTitle":705,"status":142,"phases":706,"primaryCompletion":707,"completion":280,"start":708,"enrollment":709,"conditions":710,"interventions":711},"NCT02771717","Low Exhaled NO and ICS in Suspected Asthma",[51],"2017-07","2016-05",165,[28],[691],{"trials":713,"activeCount":71},[],{"intervention":715,"totalTrials":55,"cells":716},"Duloxetine",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":738},{"trials":718,"activeCount":71},[],{"trials":720,"activeCount":71},[],{"trials":722,"activeCount":71},[],{"trials":724,"activeCount":71},[],{"trials":726,"activeCount":71},[727],{"nctId":728,"briefTitle":729,"status":129,"phases":730,"primaryCompletion":145,"completion":145,"start":731,"enrollment":732,"conditions":733,"interventions":736},"NCT02208778","Imaging Pain Relief in Osteoarthritis",[51],"2014-12",77,[734,735],"Osteoarthritis","Chronic Pain",[715,737],"Remifentanil",{"trials":739,"activeCount":71},[],{"intervention":737,"totalTrials":55,"cells":741},{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":748,"PHASE4":750,"NA":756},{"trials":743,"activeCount":71},[],{"trials":745,"activeCount":71},[],{"trials":747,"activeCount":71},[],{"trials":749,"activeCount":71},[],{"trials":751,"activeCount":71},[752],{"nctId":728,"briefTitle":729,"status":129,"phases":753,"primaryCompletion":145,"completion":145,"start":731,"enrollment":732,"conditions":754,"interventions":755},[51],[734,735],[715,737],{"trials":757,"activeCount":71},[],{"intervention":759,"totalTrials":55,"cells":760},"Rifaximin",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":781},{"trials":762,"activeCount":71},[],{"trials":764,"activeCount":71},[],{"trials":766,"activeCount":71},[],{"trials":768,"activeCount":71},[],{"trials":770,"activeCount":71},[771],{"nctId":772,"briefTitle":773,"status":129,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":780},"NCT01670149","Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea",[51],"2016-07","2012-12",151,[779],"Clostridium Difficile Infection",[759],{"trials":782,"activeCount":71},[],{"intervention":784,"totalTrials":55,"cells":785},"Simvastatin",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":806},{"trials":787,"activeCount":71},[],{"trials":789,"activeCount":71},[],{"trials":791,"activeCount":71},[],{"trials":793,"activeCount":71},[],{"trials":795,"activeCount":71},[796],{"nctId":797,"briefTitle":798,"status":129,"phases":799,"primaryCompletion":800,"completion":801,"start":417,"enrollment":8,"conditions":802,"interventions":804},"NCT01151306","The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[51],"2013-04","2013-08",[803],"Chronic Obstructive Pulmonary Disease",[784,805],"Lactose",{"trials":807,"activeCount":71},[],{"intervention":805,"totalTrials":55,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":818,"NA":824},{"trials":811,"activeCount":71},[],{"trials":813,"activeCount":71},[],{"trials":815,"activeCount":71},[],{"trials":817,"activeCount":71},[],{"trials":819,"activeCount":71},[820],{"nctId":797,"briefTitle":798,"status":129,"phases":821,"primaryCompletion":800,"completion":801,"start":417,"enrollment":8,"conditions":822,"interventions":823},[51],[803],[784,805],{"trials":825,"activeCount":71},[],{"intervention":827,"totalTrials":55,"cells":828},"Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg",{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":835,"PHASE4":837,"NA":851},{"trials":830,"activeCount":71},[],{"trials":832,"activeCount":71},[],{"trials":834,"activeCount":71},[],{"trials":836,"activeCount":71},[],{"trials":838,"activeCount":71},[839],{"nctId":840,"briefTitle":841,"status":129,"phases":842,"primaryCompletion":843,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":850},"NCT01506986","Helicobacter Eradication Aspirin Trial",[51],"2017-10-31","2022-03-16","2012-03",30024,[848,849],"Gastrointestinal Ulcer Haemorrhage","Bacterial Infection Due to Helicobacter Pylori (H. Pylori)",[827],{"trials":852,"activeCount":71},[],{"intervention":854,"totalTrials":55,"cells":855},"Polyethyleneglycol",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":864,"NA":876},{"trials":857,"activeCount":71},[],{"trials":859,"activeCount":71},[],{"trials":861,"activeCount":71},[],{"trials":863,"activeCount":71},[],{"trials":865,"activeCount":71},[866],{"nctId":867,"briefTitle":868,"status":129,"phases":869,"primaryCompletion":870,"completion":870,"start":131,"enrollment":871,"conditions":872,"interventions":875},"NCT01622972","Mode of Action of Moviprep",[51],"2014-02",72,[873,874],"Functional Constipation","Irritable Bowel Syndrome Characterized by Constipation",[854],{"trials":877,"activeCount":71},[],{"intervention":879,"totalTrials":170,"cells":880},"Azithromycin",{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":897,"PHASE3":899,"PHASE4":909,"NA":911},{"trials":882,"activeCount":71},[],{"trials":884,"activeCount":71},[885],{"nctId":886,"briefTitle":887,"status":129,"phases":888,"primaryCompletion":889,"completion":889,"start":890,"enrollment":189,"conditions":891,"interventions":896},"NCT01201577","Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals",[48],"2011-05","2009-10",[892,893,894,895],"Quorum Sensing","Prebiotics","Probiotics","Sepsis",[879],{"trials":898,"activeCount":71},[],{"trials":900,"activeCount":71},[901],{"nctId":902,"briefTitle":903,"status":142,"phases":904,"primaryCompletion":905,"completion":905,"start":635,"enrollment":282,"conditions":906,"interventions":908},"NCT02196493","An Open Label Trial of Azithromycin in Chronic Productive Cough",[50],"2016-12",[907],"Chronic Cough",[879],{"trials":910,"activeCount":71},[],{"trials":912,"activeCount":71},[],{"intervention":914,"totalTrials":55,"cells":915},"Aspirin, Dipyradimole, Clopidogrel",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":933,"NA":935},{"trials":917,"activeCount":71},[],{"trials":919,"activeCount":71},[],{"trials":921,"activeCount":71},[],{"trials":923,"activeCount":71},[924],{"nctId":925,"briefTitle":926,"status":413,"phases":927,"primaryCompletion":928,"completion":928,"start":929,"enrollment":930,"conditions":931,"interventions":932},"NCT01661322","Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke",[50],"2017-09","2009-04",3096,[21],[914],{"trials":934,"activeCount":71},[],{"trials":936,"activeCount":71},[],{"intervention":938,"totalTrials":55,"cells":939},"Transdermal glyceryl trinitrate patch",{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":946,"PHASE4":957,"NA":959},{"trials":941,"activeCount":71},[],{"trials":943,"activeCount":71},[],{"trials":945,"activeCount":71},[],{"trials":947,"activeCount":71},[948],{"nctId":949,"briefTitle":950,"status":142,"phases":951,"primaryCompletion":634,"completion":634,"start":952,"enrollment":953,"conditions":954,"interventions":955},"NCT00989716","The Efficacy of Nitric Oxide in Stroke (ENOS) Trial",[50],"2001-07",3500,[21],[938,956],"Pre-stroke antihypertensives",{"trials":958,"activeCount":71},[],{"trials":960,"activeCount":71},[],{"intervention":956,"totalTrials":55,"cells":962},{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":969,"PHASE4":975,"NA":977},{"trials":964,"activeCount":71},[],{"trials":966,"activeCount":71},[],{"trials":968,"activeCount":71},[],{"trials":970,"activeCount":71},[971],{"nctId":949,"briefTitle":950,"status":142,"phases":972,"primaryCompletion":634,"completion":634,"start":952,"enrollment":953,"conditions":973,"interventions":974},[50],[21],[938,956],{"trials":976,"activeCount":71},[],{"trials":978,"activeCount":71},[],{"intervention":980,"totalTrials":55,"cells":981},"Sustanon 250",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":988,"PHASE4":1002,"NA":1004},{"trials":983,"activeCount":71},[],{"trials":985,"activeCount":71},[],{"trials":987,"activeCount":71},[],{"trials":989,"activeCount":71},[990],{"nctId":991,"briefTitle":992,"status":142,"phases":993,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":998,"interventions":1000},"NCT03054168","Systemic Hormones and Muscle Protein Synthesis",[50],"2018-11-15","2019-02-15","2016-12-15",34,[30,999,116],"Muscle Hypotrophy",[980,1001],"Zoladex",{"trials":1003,"activeCount":71},[],{"trials":1005,"activeCount":71},[],{"intervention":1001,"totalTrials":55,"cells":1007},{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1014,"PHASE4":1020,"NA":1022},{"trials":1009,"activeCount":71},[],{"trials":1011,"activeCount":71},[],{"trials":1013,"activeCount":71},[],{"trials":1015,"activeCount":71},[1016],{"nctId":991,"briefTitle":992,"status":142,"phases":1017,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":1018,"interventions":1019},[50],[30,999,116],[980,1001],{"trials":1021,"activeCount":71},[],{"trials":1023,"activeCount":71},[],{"intervention":1025,"totalTrials":55,"cells":1026},"Dehydroepiandrosterone",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1033,"PHASE4":1045,"NA":1047},{"trials":1028,"activeCount":71},[],{"trials":1030,"activeCount":71},[],{"trials":1032,"activeCount":71},[],{"trials":1034,"activeCount":71},[1035],{"nctId":1036,"briefTitle":1037,"status":129,"phases":1038,"primaryCompletion":731,"completion":731,"start":367,"enrollment":1039,"conditions":1040,"interventions":1044},"NCT01572025","Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging",[50],60,[593,1041,1042,1043],"Ovarian Aging","Diminished Ovarian Reserve (DOR)","Predicted Poor-responders",[1025],{"trials":1046,"activeCount":71},[],{"trials":1048,"activeCount":71},[],{"intervention":1050,"totalTrials":55,"cells":1051},"Hookworm larvae",{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1053,"activeCount":71},[],{"trials":1055,"activeCount":71},[],{"trials":1057,"activeCount":71},[1058],{"nctId":1059,"briefTitle":1060,"status":129,"phases":1061,"primaryCompletion":281,"completion":281,"start":1062,"enrollment":871,"conditions":1063,"interventions":1065},"NCT01470521","Worms for Immune Regulation of Multiple Sclerosis",[49],"2011-12",[1064],"Multiple Sclerosis, Relapsing-Remitting",[1050],{"trials":1067,"activeCount":71},[],{"trials":1069,"activeCount":71},[],{"trials":1071,"activeCount":71},[],{"intervention":1073,"totalTrials":55,"cells":1074},"Live Hookworm Larvae",{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1076,"activeCount":71},[],{"trials":1078,"activeCount":71},[],{"trials":1080,"activeCount":71},[1081],{"nctId":1082,"briefTitle":1083,"status":1084,"phases":1085,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":71,"conditions":1088,"interventions":1089},"NCT00630383","Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.","WITHDRAWN",[49],"2008-05","2008-02",[26],[1073],{"trials":1091,"activeCount":71},[],{"trials":1093,"activeCount":71},[],{"trials":1095,"activeCount":71},[],{"intervention":1097,"totalTrials":55,"cells":1098},"AZD5363",{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1100,"activeCount":71},[],{"trials":1102,"activeCount":71},[],{"trials":1104,"activeCount":71},[1105],{"nctId":1106,"briefTitle":1107,"status":129,"phases":1108,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT02077569","AKT Inhibitor in Oestrogen Positive Breast Cancer",[49],"2017-02-21","2014-01",48,[1113],"Invasive Breast Cancer",[1097],{"trials":1116,"activeCount":71},[],{"trials":1118,"activeCount":71},[],{"trials":1120,"activeCount":71},[],{"intervention":1122,"totalTrials":55,"cells":1123},"Crystalloid",{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1125,"activeCount":71},[],{"trials":1127,"activeCount":71},[],{"trials":1129,"activeCount":71},[1130],{"nctId":1131,"briefTitle":1132,"status":129,"phases":1133,"primaryCompletion":684,"completion":684,"start":1134,"enrollment":199,"conditions":1135,"interventions":1139},"NCT01087853","The Effect of Crystalloids and Colloids on Visceral Blood Flow",[48,49],"2010-03",[1136,1137,1138],"Fluid Overload","Water Electrolyte Imbalance","Acid Base Imbalance",[1122,1140],"Colloid",{"trials":1142,"activeCount":71},[],{"trials":1144,"activeCount":71},[],{"trials":1146,"activeCount":71},[],{"intervention":1140,"totalTrials":55,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1150,"activeCount":71},[],{"trials":1152,"activeCount":71},[],{"trials":1154,"activeCount":71},[1155],{"nctId":1131,"briefTitle":1132,"status":129,"phases":1156,"primaryCompletion":684,"completion":684,"start":1134,"enrollment":199,"conditions":1157,"interventions":1158},[48,49],[1136,1137,1138],[1122,1140],{"trials":1160,"activeCount":71},[],{"trials":1162,"activeCount":71},[],{"trials":1164,"activeCount":71},[],{"intervention":1166,"totalTrials":55,"cells":1167},"Desmopressin",{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1169,"activeCount":71},[],{"trials":1171,"activeCount":71},[],{"trials":1173,"activeCount":71},[1174],{"nctId":1175,"briefTitle":1176,"status":129,"phases":1177,"primaryCompletion":1178,"completion":1178,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1183},"NCT03696121","Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage",[49],"2022-06-30","2019-04-01",54,[1182],"Stroke, Acute",[1166,1184],"Normal saline",{"trials":1186,"activeCount":71},[],{"trials":1188,"activeCount":71},[],{"trials":1190,"activeCount":71},[],{"intervention":1184,"totalTrials":55,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1194,"activeCount":71},[],{"trials":1196,"activeCount":71},[],{"trials":1198,"activeCount":71},[1199],{"nctId":1175,"briefTitle":1176,"status":129,"phases":1200,"primaryCompletion":1178,"completion":1178,"start":1179,"enrollment":1180,"conditions":1201,"interventions":1202},[49],[1182],[1166,1184],{"trials":1204,"activeCount":71},[],{"trials":1206,"activeCount":71},[],{"trials":1208,"activeCount":71},[],{"intervention":1210,"totalTrials":55,"cells":1211},"Clarithromycin",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1213,"activeCount":71},[],{"trials":1215,"activeCount":71},[],{"trials":1217,"activeCount":71},[1218],{"nctId":1219,"briefTitle":1220,"status":413,"phases":1221,"primaryCompletion":1222,"completion":1222,"start":1223,"enrollment":55,"conditions":1224,"interventions":1227},"NCT02416570","Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?",[49],"2015-10","2015-04",[1225,1226],"Cachexia","Lung Cancer",[1210],{"trials":1229,"activeCount":71},[],{"trials":1231,"activeCount":71},[],{"trials":1233,"activeCount":71},[],{"intervention":1235,"totalTrials":55,"cells":1236},"Tamoxifen",{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1238,"activeCount":71},[],{"trials":1240,"activeCount":71},[1241],{"nctId":1242,"briefTitle":1243,"status":142,"phases":1244,"primaryCompletion":187,"completion":1245,"start":188,"enrollment":661,"conditions":1246,"interventions":1249},"NCT02513849","Tamoxifen in Patients With Oesophageal Cancer",[48],"2018-11",[1247,1248],"Cancer","Gastrointestinal Neoplasms",[1235],{"trials":1251,"activeCount":71},[],{"trials":1253,"activeCount":71},[],{"trials":1255,"activeCount":71},[],{"trials":1257,"activeCount":71},[],{"intervention":1259,"totalTrials":55,"cells":1260},"GLP-1",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1262,"activeCount":71},[],{"trials":1264,"activeCount":71},[],{"trials":1266,"activeCount":71},[],{"trials":1268,"activeCount":71},[],{"trials":1270,"activeCount":71},[],{"trials":1272,"activeCount":71},[1273],{"nctId":1274,"briefTitle":1275,"status":129,"phases":1276,"primaryCompletion":1277,"completion":1277,"start":1278,"enrollment":189,"conditions":1279,"interventions":1280},"NCT02370745","Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle",[52],"2018-03","2014-11",[30],[1259,1281,1282,1283],"Insulin Actrapid","GIP","Intravenous amino acids",{"intervention":1281,"totalTrials":55,"cells":1285},{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1292,"PHASE4":1294,"NA":1296},{"trials":1287,"activeCount":71},[],{"trials":1289,"activeCount":71},[],{"trials":1291,"activeCount":71},[],{"trials":1293,"activeCount":71},[],{"trials":1295,"activeCount":71},[],{"trials":1297,"activeCount":71},[1298],{"nctId":1274,"briefTitle":1275,"status":129,"phases":1299,"primaryCompletion":1277,"completion":1277,"start":1278,"enrollment":189,"conditions":1300,"interventions":1301},[52],[30],[1259,1281,1282,1283],{"intervention":1282,"totalTrials":55,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1305,"activeCount":71},[],{"trials":1307,"activeCount":71},[],{"trials":1309,"activeCount":71},[],{"trials":1311,"activeCount":71},[],{"trials":1313,"activeCount":71},[],{"trials":1315,"activeCount":71},[1316],{"nctId":1274,"briefTitle":1275,"status":129,"phases":1317,"primaryCompletion":1277,"completion":1277,"start":1278,"enrollment":189,"conditions":1318,"interventions":1319},[52],[30],[1259,1281,1282,1283],{"intervention":1283,"totalTrials":55,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1330,"NA":1332},{"trials":1323,"activeCount":71},[],{"trials":1325,"activeCount":71},[],{"trials":1327,"activeCount":71},[],{"trials":1329,"activeCount":71},[],{"trials":1331,"activeCount":71},[],{"trials":1333,"activeCount":71},[1334],{"nctId":1274,"briefTitle":1275,"status":129,"phases":1335,"primaryCompletion":1277,"completion":1277,"start":1278,"enrollment":189,"conditions":1336,"interventions":1337},[52],[30],[1259,1281,1282,1283],{"intervention":1339,"totalTrials":55,"cells":1340},"Topical NSAID",{"EARLY_PHASE1":1341,"PHASE1":1343,"PHASE2":1345,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1342,"activeCount":71},[],{"trials":1344,"activeCount":71},[],{"trials":1346,"activeCount":71},[],{"trials":1348,"activeCount":71},[],{"trials":1350,"activeCount":71},[],{"trials":1352,"activeCount":71},[1353],{"nctId":1354,"briefTitle":1355,"status":129,"phases":1356,"primaryCompletion":545,"completion":545,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT03146689","Ibuprofen Gel or Capsaicin Cream for my Painful Knee Osteoarthritis?",[52],"2017-08-04",22,[1360],"Osteoarthritis, Knee",[1339,1362],"Topical Capsaicin",{"intervention":1362,"totalTrials":55,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1371,"PHASE4":1373,"NA":1375},{"trials":1366,"activeCount":71},[],{"trials":1368,"activeCount":71},[],{"trials":1370,"activeCount":71},[],{"trials":1372,"activeCount":71},[],{"trials":1374,"activeCount":71},[],{"trials":1376,"activeCount":71},[1377],{"nctId":1354,"briefTitle":1355,"status":129,"phases":1378,"primaryCompletion":545,"completion":545,"start":1357,"enrollment":1358,"conditions":1379,"interventions":1380},[52],[1360],[1339,1362],{"intervention":1382,"totalTrials":55,"cells":1383},"Pioglitazone",{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1385,"activeCount":71},[],{"trials":1387,"activeCount":71},[],{"trials":1389,"activeCount":71},[],{"trials":1391,"activeCount":71},[],{"trials":1393,"activeCount":71},[],{"trials":1395,"activeCount":71},[1396],{"nctId":1397,"briefTitle":1398,"status":129,"phases":1399,"primaryCompletion":132,"completion":1400,"start":890,"enrollment":64,"conditions":1401,"interventions":1402},"NCT02305069","Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle",[52],"2012-09",[18,30],[1382,1403,1404,1405,1406],"Insulin","Octreotide","Glucose","Mixed Amino Acids",{"intervention":1403,"totalTrials":55,"cells":1408},{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1415,"PHASE4":1417,"NA":1419},{"trials":1410,"activeCount":71},[],{"trials":1412,"activeCount":71},[],{"trials":1414,"activeCount":71},[],{"trials":1416,"activeCount":71},[],{"trials":1418,"activeCount":71},[],{"trials":1420,"activeCount":71},[1421],{"nctId":1397,"briefTitle":1398,"status":129,"phases":1422,"primaryCompletion":132,"completion":1400,"start":890,"enrollment":64,"conditions":1423,"interventions":1424},[52],[18,30],[1382,1403,1404,1405,1406],{"intervention":1404,"totalTrials":55,"cells":1426},{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1428,"activeCount":71},[],{"trials":1430,"activeCount":71},[],{"trials":1432,"activeCount":71},[],{"trials":1434,"activeCount":71},[],{"trials":1436,"activeCount":71},[],{"trials":1438,"activeCount":71},[1439],{"nctId":1397,"briefTitle":1398,"status":129,"phases":1440,"primaryCompletion":132,"completion":1400,"start":890,"enrollment":64,"conditions":1441,"interventions":1442},[52],[18,30],[1382,1403,1404,1405,1406],{"intervention":1405,"totalTrials":55,"cells":1444},{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1455},{"trials":1446,"activeCount":71},[],{"trials":1448,"activeCount":71},[],{"trials":1450,"activeCount":71},[],{"trials":1452,"activeCount":71},[],{"trials":1454,"activeCount":71},[],{"trials":1456,"activeCount":71},[1457],{"nctId":1397,"briefTitle":1398,"status":129,"phases":1458,"primaryCompletion":132,"completion":1400,"start":890,"enrollment":64,"conditions":1459,"interventions":1460},[52],[18,30],[1382,1403,1404,1405,1406],{"intervention":1406,"totalTrials":55,"cells":1462},{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1469,"PHASE4":1471,"NA":1473},{"trials":1464,"activeCount":71},[],{"trials":1466,"activeCount":71},[],{"trials":1468,"activeCount":71},[],{"trials":1470,"activeCount":71},[],{"trials":1472,"activeCount":71},[],{"trials":1474,"activeCount":71},[1475],{"nctId":1397,"briefTitle":1398,"status":129,"phases":1476,"primaryCompletion":132,"completion":1400,"start":890,"enrollment":64,"conditions":1477,"interventions":1478},[52],[18,30],[1382,1403,1404,1405,1406],{"intervention":1480,"totalTrials":55,"cells":1481},"Hartmann's solution",{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1488,"PHASE4":1490,"NA":1492},{"trials":1483,"activeCount":71},[],{"trials":1485,"activeCount":71},[],{"trials":1487,"activeCount":71},[],{"trials":1489,"activeCount":71},[],{"trials":1491,"activeCount":71},[],{"trials":1493,"activeCount":71},[1494],{"nctId":1495,"briefTitle":1496,"status":142,"phases":1497,"primaryCompletion":281,"completion":145,"start":1498,"enrollment":1499,"conditions":1500,"interventions":1502},"NCT02136277","Vascular Changes During Colorectal Surgery",[],"2015-01",32,[1501],"Patients Undergoing Open Resection of Colorectal Tumours",[1480],{"intervention":1504,"totalTrials":55,"cells":1505},"sodium phenylbutyrate",{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1514,"NA":1516},{"trials":1507,"activeCount":71},[],{"trials":1509,"activeCount":71},[],{"trials":1511,"activeCount":71},[],{"trials":1513,"activeCount":71},[],{"trials":1515,"activeCount":71},[],{"trials":1517,"activeCount":71},[1518],{"nctId":1519,"briefTitle":1520,"status":129,"phases":1521,"primaryCompletion":1522,"completion":1523,"start":1524,"enrollment":1525,"conditions":1526,"interventions":1528},"NCT05028803","The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino Acids",[52],"2023-09-01","2024-03-01","2021-09-01",8,[1527],"Obese Non Diabetic",[1504],{"intervention":1530,"totalTrials":55,"cells":1531},"Blood and urine sampling",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1533,"activeCount":71},[],{"trials":1535,"activeCount":71},[],{"trials":1537,"activeCount":71},[],{"trials":1539,"activeCount":71},[],{"trials":1541,"activeCount":71},[],{"trials":1543,"activeCount":71},[1544],{"nctId":1545,"briefTitle":1546,"status":142,"phases":1547,"primaryCompletion":1548,"completion":1548,"start":1222,"enrollment":282,"conditions":1549,"interventions":1551},"NCT03578523","Renal MR Feasibility in Renal Disease",[],"2020-12",[1550],"Renal Disease",[1530,1552],"Iohexol clearance test",{"intervention":1552,"totalTrials":55,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1561,"PHASE4":1563,"NA":1565},{"trials":1556,"activeCount":71},[],{"trials":1558,"activeCount":71},[],{"trials":1560,"activeCount":71},[],{"trials":1562,"activeCount":71},[],{"trials":1564,"activeCount":71},[],{"trials":1566,"activeCount":71},[1567],{"nctId":1545,"briefTitle":1546,"status":142,"phases":1568,"primaryCompletion":1548,"completion":1548,"start":1222,"enrollment":282,"conditions":1569,"interventions":1570},[],[1550],[1530,1552],{"intervention":1572,"totalTrials":55,"cells":1573},"Levobupivicaine 0.25%",{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1575,"activeCount":71},[],{"trials":1577,"activeCount":71},[],{"trials":1579,"activeCount":71},[],{"trials":1581,"activeCount":71},[],{"trials":1583,"activeCount":71},[],{"trials":1585,"activeCount":71},[1586],{"nctId":1587,"briefTitle":1588,"status":129,"phases":1589,"primaryCompletion":131,"completion":1062,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1596},"NCT00830089","Trial of a Transversus Abdominis Plane (TAP) Block in Laparoscopic Colorectal Surgery",[52],"2009-09",66,[1593,1594,1595],"Post-operative Pain","Postoperative Nausea","Postoperative Complications",[1572],{"intervention":1598,"totalTrials":55,"cells":1599},"Carvedilol",{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1601,"activeCount":71},[],{"trials":1603,"activeCount":71},[],{"trials":1605,"activeCount":71},[],{"trials":1607,"activeCount":71},[],{"trials":1609,"activeCount":71},[],{"trials":1611,"activeCount":71},[1612],{"nctId":1613,"briefTitle":1614,"status":142,"phases":1615,"primaryCompletion":1616,"completion":1617,"start":198,"enrollment":418,"conditions":1618,"interventions":1622},"NCT03114813","Can MRI Evaluate Beta-blocker Response in Portal Hypertension?",[],"2019-07","2024-01",[1619,1620,1621],"Liver Cirrhosis","Portal Hypertension","Varix, Esophageal",[1598],{"intervention":1624,"totalTrials":55,"cells":1625},"Anti-IL5 Antibody",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1627,"activeCount":71},[],{"trials":1629,"activeCount":71},[],{"trials":1631,"activeCount":71},[],{"trials":1633,"activeCount":71},[],{"trials":1635,"activeCount":71},[],{"trials":1637,"activeCount":71},[1638],{"nctId":1639,"briefTitle":1640,"status":142,"phases":1641,"primaryCompletion":1642,"completion":1643,"start":1644,"enrollment":282,"conditions":1645,"interventions":1646},"NCT04114396","Poor Response to Monoclonal Therapy in Asthma",[],"2021-06-30","2021-07-31","2018-12-31",[28],[1624],{"intervention":1648,"totalTrials":55,"cells":1649},"Prohance",{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1651,"activeCount":71},[],{"trials":1653,"activeCount":71},[],{"trials":1655,"activeCount":71},[],{"trials":1657,"activeCount":71},[],{"trials":1659,"activeCount":71},[],{"trials":1661,"activeCount":71},[1662],{"nctId":1663,"briefTitle":1664,"status":142,"phases":1665,"primaryCompletion":1666,"completion":1666,"start":198,"enrollment":1667,"conditions":1668,"interventions":1669},"NCT02481882","Baseline Cortical Haemodynamics in MS",[52],"2019-10",80,[26],[1648],{"intervention":1671,"totalTrials":55,"cells":1672},"Acetazolamide",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1674,"activeCount":71},[],{"trials":1676,"activeCount":71},[],{"trials":1678,"activeCount":71},[],{"trials":1680,"activeCount":71},[],{"trials":1682,"activeCount":71},[],{"trials":1684,"activeCount":71},[1685],{"nctId":1686,"briefTitle":1687,"status":129,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":34,"conditions":1691,"interventions":1693},"NCT03107429","Effect of Acetazolamide on Intraocular Pressure After Being in the Trendelenburg Position.",[52],"2015-10-01","2015-03-01",[1692],"IOP",[1671],{"intervention":1695,"totalTrials":55,"cells":1696},"Bisacodyl",{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1698,"activeCount":71},[],{"trials":1700,"activeCount":71},[],{"trials":1702,"activeCount":71},[],{"trials":1704,"activeCount":71},[],{"trials":1706,"activeCount":71},[],{"trials":1708,"activeCount":71},[1709],{"nctId":1710,"briefTitle":1711,"status":142,"phases":1712,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1719},"NCT03226145","Reclassifying Constipation Using Imaging and Manometry",[52],"2020-09","2021-06","2017-07-20",120,[1718,874],"Constipation - Functional",[1695,1720],"Hyoscine butylbromide",{"intervention":1720,"totalTrials":55,"cells":1722},{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1724,"activeCount":71},[],{"trials":1726,"activeCount":71},[],{"trials":1728,"activeCount":71},[],{"trials":1730,"activeCount":71},[],{"trials":1732,"activeCount":71},[],{"trials":1734,"activeCount":71},[1735],{"nctId":1710,"briefTitle":1711,"status":142,"phases":1736,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":1737,"interventions":1738},[52],[1718,874],[1695,1720],{"intervention":1740,"totalTrials":55,"cells":1741},"Lipopolysaccharide",{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1748,"PHASE4":1750,"NA":1752},{"trials":1743,"activeCount":71},[],{"trials":1745,"activeCount":71},[],{"trials":1747,"activeCount":71},[],{"trials":1749,"activeCount":71},[],{"trials":1751,"activeCount":71},[],{"trials":1753,"activeCount":71},[1754],{"nctId":1755,"briefTitle":1756,"status":129,"phases":1757,"primaryCompletion":776,"completion":776,"start":325,"enrollment":1758,"conditions":1759,"interventions":1760},"NCT01423968","Effect of Lipopolysaccharide on Skeletal Muscle Functions",[52],6,[895],[1740],{"intervention":1762,"totalTrials":55,"cells":1763},"Northern Hemisphere Influenza Vaccine 2017\u002F18",{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1768,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1765,"activeCount":71},[],{"trials":1767,"activeCount":71},[],{"trials":1769,"activeCount":71},[],{"trials":1771,"activeCount":71},[],{"trials":1773,"activeCount":71},[],{"trials":1775,"activeCount":71},[1776],{"nctId":1777,"briefTitle":1778,"status":129,"phases":1779,"primaryCompletion":1780,"completion":1781,"start":1782,"enrollment":1783,"conditions":1784,"interventions":1786},"NCT03144518","Mood and Influenza Vaccine Response: A Feasibility Trial",[52],"2017-11-01","2018-05-31","2017-09-01",106,[1785],"Vaccination; Infection",[1762],{"intervention":1788,"totalTrials":55,"cells":1789},"Exenatide",{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1796,"PHASE4":1798,"NA":1800},{"trials":1791,"activeCount":71},[],{"trials":1793,"activeCount":71},[],{"trials":1795,"activeCount":71},[],{"trials":1797,"activeCount":71},[],{"trials":1799,"activeCount":71},[],{"trials":1801,"activeCount":71},[1802],{"nctId":1803,"briefTitle":1804,"status":129,"phases":1805,"primaryCompletion":776,"completion":776,"start":1590,"enrollment":1525,"conditions":1806,"interventions":1808},"NCT01046721","Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms",[52],[1807],"Type 2 Diabetes",[1788,1809],"Saline",{"intervention":1809,"totalTrials":55,"cells":1811},{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1816,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1813,"activeCount":71},[],{"trials":1815,"activeCount":71},[],{"trials":1817,"activeCount":71},[],{"trials":1819,"activeCount":71},[],{"trials":1821,"activeCount":71},[],{"trials":1823,"activeCount":71},[1824],{"nctId":1803,"briefTitle":1804,"status":129,"phases":1825,"primaryCompletion":776,"completion":776,"start":1590,"enrollment":1525,"conditions":1826,"interventions":1827},[52],[1807],[1788,1809],{"intervention":1829,"totalTrials":55,"cells":1830},"Administration of phenylephrine",{"EARLY_PHASE1":1831,"PHASE1":1833,"PHASE2":1835,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1832,"activeCount":71},[],{"trials":1834,"activeCount":71},[],{"trials":1836,"activeCount":71},[],{"trials":1838,"activeCount":71},[],{"trials":1840,"activeCount":71},[],{"trials":1842,"activeCount":71},[1843],{"nctId":1844,"briefTitle":1845,"status":142,"phases":1846,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1525,"conditions":1849,"interventions":1851},"NCT02252627","The Effect of Phenylephrine and Ephedrine on Microvascular Blood Flow",[],"2015-08","2014-08",[1850],"Healthy Volunteers",[1829,1852],"Administration of ephedrine",{"intervention":1852,"totalTrials":55,"cells":1854},{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1856,"activeCount":71},[],{"trials":1858,"activeCount":71},[],{"trials":1860,"activeCount":71},[],{"trials":1862,"activeCount":71},[],{"trials":1864,"activeCount":71},[],{"trials":1866,"activeCount":71},[1867],{"nctId":1844,"briefTitle":1845,"status":142,"phases":1868,"primaryCompletion":1847,"completion":1847,"start":1848,"enrollment":1525,"conditions":1869,"interventions":1870},[],[1850],[1829,1852],{"intervention":1872,"totalTrials":55,"cells":1873},"Inhaled corticosteroid dose\u002Ftype",{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1875,"activeCount":71},[],{"trials":1877,"activeCount":71},[],{"trials":1879,"activeCount":71},[],{"trials":1881,"activeCount":71},[],{"trials":1883,"activeCount":71},[],{"trials":1885,"activeCount":71},[1886],{"nctId":1887,"briefTitle":1888,"status":129,"phases":1889,"primaryCompletion":1890,"completion":1890,"start":588,"enrollment":871,"conditions":1891,"interventions":1892},"NCT02671773","Characterising the Microbiota in Asthma",[],"2015-06",[28],[1872],{"intervention":1894,"totalTrials":55,"cells":1895},"Saccharomyces Cerevisiae CNCM I-3856",{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1902,"PHASE4":1904,"NA":1906},{"trials":1897,"activeCount":71},[],{"trials":1899,"activeCount":71},[],{"trials":1901,"activeCount":71},[],{"trials":1903,"activeCount":71},[],{"trials":1905,"activeCount":71},[],{"trials":1907,"activeCount":71},[1908],{"nctId":1909,"briefTitle":1910,"status":1084,"phases":1911,"primaryCompletion":1912,"completion":416,"start":1913,"enrollment":71,"conditions":1914,"interventions":1916},"NCT00977587","Saccharomyces Cerevisiae CNCM I-3856 Treatment in Irritable Bowel Syndrome With Diarrhea (IBS-D) and Post Infective Bowel Dysfunction",[52],"2012-01","2011-01",[23,1915],"Post Infective Bowel Dysfunction",[1894],{"intervention":1918,"totalTrials":55,"cells":1919},"Microarray",{"EARLY_PHASE1":1920,"PHASE1":1922,"PHASE2":1924,"PHASE3":1926,"PHASE4":1928,"NA":1930},{"trials":1921,"activeCount":71},[],{"trials":1923,"activeCount":71},[],{"trials":1925,"activeCount":71},[],{"trials":1927,"activeCount":71},[],{"trials":1929,"activeCount":71},[],{"trials":1931,"activeCount":71},[1932],{"nctId":1933,"briefTitle":1934,"status":129,"phases":1935,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":9,"conditions":1938,"interventions":1940},"NCT04323683","The Effect of Progesterone on Human Endometrium",[],"2019-07-31","2019-02-01",[1939],"Fertility",[1918]]